Mountain states Mormonism misleads on marijuana

Twenty-four U.S. states have legalized sales of recreational marijuana, yet parts of the Rocky Mountain West remain steadfast in their opposition to cannabinoids. One reason is state and local political domination by the LDS or Mormon Church. Starting in 1915 Mormons made marijuana taboo.

A hundred years later problems with Mormonism’s public image resulted in an attempt to rebrand itself exclusively as the Church of Jesus Christ of Latter-day Saints. Try as it may, Mormonism cannot outrun the history of its attitudes toward marijuana. It clearly outlined its position on cannabis and drugs in its out-of-print 1992 edition of the Encyclopedia of Mormonism:

In addition to avoiding tea, coffee, and alcoholic beverages, members should not misuse legal drugs, and should not use any substance that contains illegal drugs or other harmful or habit forming ingredients.

The Encyclopedia goes on to contrast Mormonism with the drug awareness of other religions in a holier-than-thou ranking system that uses marijuana legalization as its moral benchmark:

Legalization of Marijuana: Only one in ten Latter-day Saints supports the legalization of marijuana, compared with about two in ten among Protestants and Catholics. Forty-one percent of Jews and half of those with no religion favor legalization of marijuana. [NORC pooled surveys for 1972-1988]

If someone wanted to construct criminal laws in which a higher probability of arrest falls upon Jews, non-believers and people other than themselves, few better options exist than making marijuana illegal and creating draconian penalties for its use. Faith alone cannot justify the constitutionality of anti-marijuana laws. That would be an illegal establishment of religion by the government. Something more organic or scary is needed.

Prior to and after World War II, Jews and non-believers were often lumped together with Communists. Mormonism was strongly tied to the anti-Communist John Birch Society by one of its biggest fans, church president Ezra Taft Benson (1899-1994). Benson and the Birchers believed legalizing marijuana and water fluoridation were Communist plots. Fluoridation has since been cleared of all charges of Communism by medical science.

Marijuana criminalization remains useful to religious isolationists living in remote towns and villages because its illegality discourages certain undesirables from traveling, working or retiring there. Anti-marijuana laws give Mormons and other prohibitionists an edge when it comes to government employment. Persons applying for a drug enforcement job with the DEA, or the FBI which also covers drug cases, will be summarily rejected if they have tried cannabinoids only once in their lives. Service in the military is unlikely with marijuana or other drug arrests. Security clearances will be denied. All it takes are polygraphs or a positive urine test to terminate a government career.

Persecuting marijuana consumers creates easier pathways for anti-marijuana religious groups to take over government agencies. In one example Mormon FBI managers attempted to usurp the bureaucracy—if not the whole of the FBI—only to be busted in 1989 for discriminating in the hiring, training and treatment of Hispanic job applicants. The offending agents also targeted FBI employees possessing seniority and perfect job performances based solely on skin color, culture, and ethnicity. The Book of Mormon labels darker skinned people as “Lamanites” who it says are “loathsome” since they are believed to be the descendants of Laman and are thereby allegedly cursed for their evil nature and corruption. It goes on to proclaim that Lamanites can repent and embrace the Book of Mormon and automatically become “white and delightsome”. A landmark lawsuit brought by Hispanic FBI agents, Mat Perez vs. FBI, resulted in the presiding judge ordering the FBI to clean up its act.

The LDS Church has experienced a declining membership since 2013 in contrast to cannabinoids which show a tolerance or popularity increase that now encompasses 70-percent of adult Americans. The Church’s declining membership has several sources: lower birth rates, modernism, science, secularism, eroding beliefs, its cover-up of its neglect of charitable functions, and a scandal in which shell companies were used to disguise its ownership of for-profit businesses and other organizations. Typically left out of the calculation is the Church’s disdain and persecution of consumers of a plant the ancient Egyptians referred to as the “branches of bliss”. It’s possible that many Mormons who once regarded Mormonism as their preferred drug switched to a better one. Certainly few of those who enjoy branches of bliss today would give it up merely to join the Latter-day Saints.

This entry was posted in Servetus. Bookmark the permalink.

19 Responses to Mountain states Mormonism misleads on marijuana

  1. One thing the JBS never learned: the Communist regimes of the 20th century supported Marijuana criminalization, going as far as having users and dealers shot without trial. (Ditto for other drugs.) Just look up Operation Black Poppy that the Soviet Union enacted.

  2. Servetus says:

    Mormonism’s rejection of tea and coffee consumption can have cancerous consequences:

    23-Dec-2024 — Can drinking coffee or tea help prevent head and neck cancer? Pooled analysis of numerous studies suggests a potentially protective effect.

    In a recent analysis of data from more than a dozen studies, coffee and tea consumption was linked with lower risks of developing head and neck cancer, including cancers of the mouth and throat. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.

    Head and neck cancer is the seventh most common cancer worldwide, and rates are rising in low- and middle-income countries. Many studies have assessed whether drinking coffee or tea is associated with head and neck cancer, with inconsistent results.

    To provide additional insight, investigators examined data from 14 studies by different scientists associated with the International Head and Neck Cancer Epidemiology consortium, a collaboration of research groups around the globe. Study participants completed questionnaires about their prior consumption of caffeinated coffee, decaffeinated coffee, and tea in cups per day/week/month/year.

    When investigators pooled information on 9,548 patients with head and neck cancer and 15,783 controls without cancer, they found that compared with non-coffee-drinkers, individuals who drank more than 4 cups of caffeinated coffee daily had 17% lower odds of having head and neck cancer overall, 30% lower odds of having cancer of the oral cavity, and 22% lower odds of having throat cancer. Drinking 3–4 cups of caffeinated coffee was linked with a 41% lower risk of having hypopharyngeal cancer (a type of cancer at the bottom of the throat).

    Drinking decaffeinated coffee was associated with 25% lower odds of oral cavity cancer. Drinking tea was linked with 29% lower odds of hypopharyngeal cancer. Also, drinking 1 cup or less of tea daily was linked with a 9% lower risk of head and neck cancer overall and a 27% lower risk of hypopharyngeal cancer, but drinking more than 1 cup was associated with 38% higher odds of laryngeal cancer.

    “While there has been prior research on coffee and tea consumption and reduced risk of cancer, this study highlighted their varying effects with different sub-sites of head and neck cancer, including the observation that even decaffeinated coffee had some positive impact,” said senior author Yuan-Chin Amy Lee, PhD, of Huntsman Cancer Institute and the University of Utah School of Medicine. “Coffee and tea habits are fairly complex, and these findings support the need for more data and further studies around the impact that coffee and tea can have on reducing cancer risk.” […]

    AAAS Public Science News Release: Can drinking coffee or tea help prevent head and neck cancer? Pooled analysis of numerous studies suggests a potentially protective effect

    CANCER: Coffee and tea consumption and the risk of head and neck cancer: An updated pooled analysis in the International Head and Neck Cancer Epidemiology Consortium

    Authors: Timothy Nguyen MPH, Alzina Koric PhD, Chun-Pin Esther Chang PhD, Christine Barul PhD, Loredana Radoi DDS, PhD, Diego Serraino MD, Mark P. Purdue PhD, Karl T. Kelsey MD, MOH, Michael D. McClean ScD, Eva Negri PhD, Valeria Edefonti PhD, Kirsten Moysich PhD, MS, Zuo-Feng Zhang MD, PhD, Hal Morgenstern PhD, Fabio Levi MD, Thomas L. Vaughan MD, MPH, Carlo La Vecchia MD, MSc, Werner Garavello MD, Richard B. Hayes DDS, PhD, Simone Benhamou PhD, Stimson P. Schantz MD, Guo-Pei Yu MD, MPH, Hermann Brenner MD, Shu-Chun Chuang PhD, Paolo Boffetta MD, MPH, Mia Hashibe PhD,
    Yuan-Chin Amy Lee PhD.

  3. Servetus says:

    The American Psychiatric Association (APA) focuses on psychedelic medications:

    1-Jan-2025 — As the body of research grows around the potential promise of psychedelic medications in psychiatry, many questions and challenges remain. The January issue of the American Journal of Psychiatry features a series of articles, including new research, reviews and commentaries, on the use of these treatments.

    The issue addresses many of the ongoing challenges and looming questions in the field of psychiatric psychedelic research and treatment. These include issues relevant to basic pharmacology and effects on neural circuits, evidence of clinical efficacy, methodological challenges/ limitations of existing research (such as possibly large expectancy effects and functional unblinding), and contextual factors pertaining to public health and policy considerations. Other issues include drug interactions; whether patients can experience therapeutic benefits without experiencing the altered state (“psychedelic experience”) associated with psychedelic treatments; and the role of the drug (regulated by the FDA), the role of the psychological support/therapy component (likely not to be FDA-regulated) and the interaction of the two in treatment.

    “Sufficiently addressing and answering these scientific and clinical questions will be critical for the future clinical success of these agents,” AJP’s Editor-in-Chief Ned Kalin, M.D., writes […]

    A few of the articles from the issue are highlighted below:

    “Psychedelics for the Treatment of Psychiatric Disorders: Methodologic Considerations and Guidance for Future Research, Clinical Development and Implementation,” Roger S. McIntyre, M.D. et al. — This review addresses general methodological considerations for psychedelic clinical trial data and provides recommendations. The paper is intended to help facilitate the interpretability and translatability of psychedelic studies and provides guidance for their future research and implementation, to ensure that development of psychedelic treatments is rigorous with respect to safety and the actual benefits of these treatments.

    “Single-dose Psilocybin for Depression with Severe Treatment Resistance: a Non-Randomized Controlled Trial,” Scott T. Aaronson, M.D., et al. — Original research from Aaronson and colleagues describes positive findings from an open-label trial of psilocybin treatment in individuals with severe treatment-resistant depression. This small open-label study demonstrated significant safety and efficacy of synthetic psilocybin in severe treatment resistant depression.

    “Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression,” Johannes G. Ramaekers, Ph.D., et al. — Ramaekers and colleagues review the evidence for ultra-fast, short-acting psychedelics such as dimethyltryptamine and 5-methoxy-dimethyltryptamine (5-MeO-DMT and DMT) which potentially offer benefits such as individualized dosing regimens to maximize treatment outcome and facilitate less complex and less costly implementation.

    “Primum Non Nocere: The Onus to Characterize the Potential Harms of Psychedelic Treatment” Sharmin Ghaznavi, M.D., Ph.D., et al. — As with all therapeutic interventions, research is needed not only into their benefits, but also potential risks, including scrutiny in broad populations with psychiatric and medical comorbidities typically excluded from clinical trials. Among the known and potential harms of psychedelic treatments reviewed by Ghaznavi and colleagues include enduring perceptual disturbances; overuse, misuse and dependence; challenging experiences or “bad trips”; acute and cumulative cardiovascular effects; and more. They also make recommendations for further research and monitoring.

    AAAS Public Science News Release: Special issue of APA’s official journal focuses on psychedelic medication

    Special issue of APA’s official journal focuses on psychedelic medication: Peer-Reviewed Publication, American Psychiatric Association.

    Position Statement on the Use of Psychedelic and Empathogenic Agents for Mental Health Conditions

    For a copy of full articles, contact press@psych.org

  4. NorCalNative says:

    Servetus, any thoughts on whether tripping is essential to achieving therapuetic goals with psychedelics?

    • Servetus says:

      I take psilocybin microdoses that come conveniently encapsulated in precisely measured strengths (1532 micrograms) from Zide Door—Church of Ambrosia here in the Bay Area. The 20 capsules come in a small bottle labeled “Vibrant Minds—Makilla Gorilla”. I can take one capsule before bed and wake up feeling refreshed and more positive about things in general after experiencing longer and more enhanced dreams. I usually wait a few weeks before taking it again.

      My experience from Zide Door’s DMT vape pen is different. I get a slight body effect from it immediately and then a more relaxed mindset follows. An interesting thing I notice in the days following its use is that my startle reflex has changed. For instance, my cat can jump onto my desk unexpectedly without me being surprised or tensing up about it. I seem to instantly recognize what is happening and I don’t react emotionally.

      Neither DMT nor psilocybin causes me to hallucinate, even when I take a full mushroom dose (about 22,000 micrograms). The two drugs’ physical and mental effects are nowhere near the space launch I experienced with my first LSD trip in the 70s. If I were to find a source and take acid again I would take it in microdoses.

      • My Name says:

        My thoughts on the article “Mountain states Mormonism misleads on marijuana” are that it highlights the complex relationship between Mormonism and marijuana laws in mountain states. The article suggests that Mormonism has played a significant role in shaping public opinion and policy on marijuana, often in ways that are misleading or inaccurate. As someone interested in drug policy, I appreciate the article’s nuanced exploration of this topic and the ways in which religious beliefs can influence political decisions. I hope that this article will contribute to a more informed and thoughtful discussion about marijuana policy in these states.

      • Son of Sam Walton says:

        Happy New Years guys. The psychedelic affect might be necessary for a faster result. Small amounts (micro-dose) might be nearly impossible to notice therapeutic effects right off, unlike a psychedelic dose. For emergencies, it might be necessary to take enough to trip, but afterwards, a smart move to take small amounts twice a week/once a week for long term therapeutic effects. Like the difference between a little bit of sugar or a lot in a tea to give it the true flavor of ‘Sweet Tea’ . . . like one table-spoon of sugar in a gallon of tea will still taste bitter to the point one may not even notice the sugar added . . . keep adding sugar and the taste becomes obvious to just overbearingly sweet.

        You don’t hallucinate at all on Mushrooms, Servetus? I hallucinate on doses as small as two grams and often get killed in WWII on doses as high as seven grams (twice, I’ve died in WWII, once on D-Day in the water on the beach and another time while flying a bomber over Germany) . . . ten grams, I witness the creation of the world. My standard dose is between 2.5 and 4 grams. Anything from colors, chasers, walls melting/pulsating, patterns moving/altering on the floor, . . . amazing closed eye visuals, with thick reverberating sound distortions one can almost feel, like wind or a pulsating beat hitting the ear and hair . . . and warm massages up and down my sides, like the feel of fingers on the skin.

        I wonder if you have a tolerance to mushrooms, where the ‘whole’ affect won’t kick in. Example, for me, there is no difference between eating 1mg of THC and 2,000mg of THC. But give my wife as low as 25mg, she’s on another planet, and desperately finding the safety manual connected to the couch for safe reentry back to earth . . . 50mg and she’s high two days in a row.

        Do you soak your dried mushrooms in lemon juice for at least fifteen minutes? I only Lemon-tek my mushrooms, which allows them to kick in about twenty minutes and in no time, you are peaking and after three hours, your trip is done. Who has six hours to trip?

        If I’m at home and I keep my eyes open, then my trip can usually cause me uncomfortable emotions/anxiety in regards to life in general, but if I close my eyes, then my consciousness doesn’t try to wreck my mood. I’m sure its different when I’m out in nature.

        I hear mescaline is more geometric in visuals and is less likely to create any negative or bad trips.

        • Servetus says:

          I don’t know why I don’t react more strongly to psilocybin. I took a lot of acid in my early days and I noted that the later trips were never as intense as my first one. In the first trip my brain separated into three minds with one producing a laser light show before laser light shows existed, another composing classical music that I couldn’t remember afterwards, and the third objectively observing it all in absolute awe of what my brain was capable of doing. That never happened again. It could be the brain develops a tolerance to psychedelics. I have no way of knowing.

          I haven’t tried a lemon juice magic mushroom cocktail, although it sounds interesting. Drinking grapefruit juice is known for speeding up the intake of drugs, maybe that’s it.

  5. Servetus says:

    A British company with a manufacturing plant in Bulgaria was sent a warning letter by the FDA because it is selling a CBD infused tampon in the U.S. that has not undergone FDA approval:

    03-JAN-2024 – “…your firm’s labeling and promotion of the device provides evidence that the device is intended for relief of period-related pain, which would constitute a major change or modification to its intended use, for which your firm lacks clearance or approval,” the FDA wrote.

    “Our inspection and review of your website opens in a new tab or window determined that the CBD Daye Tampon is adulterated … because your firm does not have an approved application for premarket approval … or an approved application for an investigational device exemption,” said the letter, which was signed by Michael Hoffmann, director of the FDA’s Office of GastroRenal, ObGyn, General Hospital, and Urology Devices.

    “The CBD Daye Tampon is also misbranded … because your firm introduced or delivered for introduction into interstate commerce for commercial distribution this device with major changes or modifications to the intended use without submitting a new premarket notification to FDA,” the letter continued. “The device is further misbranded because your firm did not notify FDA regarding changes and modifications in the device that could significantly affect the safety or effectiveness of the device.”

    The warning letter discussed a series of back-and-forth communication between the company and the FDA. […]

    MedPage Today: CBD-Coated Tampons? FDA Says No Way

  6. Servetus says:

    A single dose of psilocybin is effective for treatment-resistant depression:

    20-Dec-2024 — Objective: Depression varies along a difficulty-to-treat spectrum. Patients whose illness fails to respond to at least five treatments may be considered to have severely treatment-resistant depression (TRD). The objective of this study was to document the safety and efficacy of psilocybin in patients with severe TRD.

    Methods: This was a 12-week, open-label trial conducted at Sheppard Pratt Hospital. Participants were 18–65 years of age, in a major depressive episode with documented insufficient benefit from at least five treatments during the current episode. A single dose of synthetic psilocybin (25 mg) was administered. Psychotropic medications were discontinued at least 2 weeks prior to dosing through at least 3 weeks post-dosing. Therapists met with patients for three sessions during pretreatment, during the 8-hour dosing day, and for three integration sessions posttreatment. The primary outcome measure was change in Montgomery-Åsberg Depression Rating scale (MADRS) at 3 weeks posttreatment. Secondary measures including MADRS scores up to 12 weeks posttreatment, and subject-rated scales capturing depression and level of function were completed at baseline and all subsequent visits.

    Results: Twelve participants (six male, six female; mean age=40.6 years [SD=9.6]) with severe TRD were followed over the study period. Depressive symptoms were significantly decreased at week 3 (MADRS least-squares mean change=−15.8, 95% CI=−25.4 to −6.3) and Week 12 (MADRS least-squares mean change=−17.2, 95% CI=−25.2 to −9.1). In exploratory analyses, the Oceanic Boundlessness (OB) dimension of the psychedelic experience correlated with post-dosing antidepressant responses. Patients with comorbid PTSD (N=5) showed significantly less antidepressant effect of psilocybin. […]

    Authors: Scott T. Aaronson, M.D., Andrew van der Vaart, M.D., Ph.D., Tammy Miller, Psy.D., Jeffrey LaPratt, Psy.D., Kimberly Swartz, B.S.N., Audrey Shoultz, B.S., Margo Lauterbach, M.D., Trisha Suppes, M.D., Ph.D., and Harold A. Sackeim, Ph.D.

    Psychiatry Online: Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial

  7. Servetus says:

    Opioid misuse is less in states with medical marijuana availability:

    13-Jan-2025 — By the end of 2019, 32 states had adopted medical marijuana laws (MCL) alone. All states that went on to adopt recreational marijuana laws (RCL) had previously adopted an MCL.

    Using National Survey on Drug Use and Health (NSDUH) data from 2015-2019, the researchers estimated cannabis law associations with opioid (prescription opioid misuse and/or heroin use) misuse and use disorder. […]

    “Our study is the first to investigate the effects of cannabis laws on opioid outcomes among people that used cannabis in the past year and that initiated cannabis use prior to cannabis law adoption in their state,” noted Silvia Martins, MD, PhD, professor of Epidemiology at Columbia Mailman School. “Much has been speculated on whether the enactment of medical and recreational cannabis laws can have a role in decreasing prescriptions for opioid pain relievers, opioid use and misuse, opioid use disorder, and overdose in the U.S.”

    Martins continues, “Comparing individuals in states with medical cannabis laws alone to those in states without such laws, we found an inconsistent pattern of decreased odds of opioid outcomes, which were more pronounced among people reporting cannabis use. The pattern did not hold for individuals in states with recreational cannabis laws, suggesting that MCLs may be associated with reductions in opioid use among people using cannabis but additional work to replicate and expand on these findings is needed.”

    Overall, MCL and RCL adoption were not associated with changes in the odds of any opioid outcome. After restricting to respondents reporting past-year cannabis use, decreased odds of past year opioid misuse were observed among individuals in states with MCL compared to those in states without cannabis laws. RCLs were not associated with changes in the odds of any opioid outcome beyond MCL adoption […]

    AAAS Public Science News Release: Study finds changes in opioid use outcomes after passage of medical marijuana laws

    Science Daily: Changes in opioid use outcomes after passage of medical marijuana laws

  8. Servetus says:

    Mormons need to reconsider their prohibition of coffee now that a team of scientists has demonstrated that morning coffee intake results in a lowered risk of all-cause and cardiovascular mortality:

    Jan 7 2025…health benefits of coffee may be limited to morning cups of joe, according to an observational study based on the National Health and Nutrition Examination Survey (NHANES).

    Compared with non-coffee drinkers, those who mostly drank coffee in the morning had a lower risk of all-cause mortality (adjusted HR 0.84, 95% CI 0.74-0.95) and cardiovascular mortality (HR 0.69, 95% CI 0.55-0.87) when followed over a median 9.8 years.

    It appeared that survival was particularly improved with morning consumers drinking moderate (>1 to 2 cups and >2 to 3 cups/day) and heavy (>3 cups/day) amounts of coffee rather than lesser amounts, reported Lu Qi, MD, PhD, epidemiologist of Tulane University in New Orleans and Harvard T.H. Chan School of Public Health in Boston, and colleagues in European Heart Journal.

    In contrast, people who kept drinking coffee later in the day, the all-day type, had no reduction in all-cause mortality (HR 0.96, 95% CI 0.83-1.12) and cardiovascular mortality (HR 0.82, 95% CI 0.61-1.10) regardless of how much they consumed. […]

    The authors suggested two potential mechanisms that could explain their findings. One is that all-day caffeine consumption can disrupt circadian rhythms. Secondly, there may be anti-inflammatory substances within coffee that can counteract the body’s pro-inflammatory cytokines when they are typically at their highest levels in the morning.

    “Why would time of the day matter? In the morning hours there is commonly a marked increase in sympathetic activity as we wake up and get out of bed, an effect that fades away during the day and reaches its lowest level during sleep. Thus, it is possible, as the authors point out, that coffee drinking in the afternoon or evening disrupts the circadian rhythm of sympathetic activity,” agreed Thomas Lüscher, MD, cardiologist of Royal Brompton and Harefield Hospitals in London and the University of Zurich, writing in an accompanying editorial. […]

    MedPage Today: Coffee Drinking Tied to Better Survival, but Timing Matters — Lower risk of all-cause and cardiovascular mortality observed only among morning drinkers

    Authors: Xuan Wang, Hao Ma, Qi Sun, Jun Li, Yoriko Heianza, Rob M Van Dam, Frank B Hu, Eric Rimm, JoAnn E Manson, Lu Qi.

  9. Servetus says:

    Higher green tea consumption in Japan is associated with fewer cerebral white matter lesions and may be useful in preventing dementia:

    07 January 2025 — This study investigated the association between green tea or coffee consumption with cerebral white matter lesions and hippocampal and total brain volumes among 8766 community-dwelling participants recruited from the Japan Prospective Studies Collaboration for Aging and Dementia between 2016 and 2018. A Food Frequency Questionnaire was used to assess green tea and coffee consumption, whereas brain magnetic resonance imaging was performed to assess cerebral white matter lesions, hippocampal volume, and total brain volume. Multivariable-adjusted analysis revealed significant correlations between fewer cerebral white matter lesions and higher green tea consumption, whereas no significant differences were found between green tea consumption and hippocampal or total brain volume. Regarding coffee consumption, no significant differences were observed in cerebral white matter lesions or hippocampal or total brain volumes. Hence, higher green tea consumption was associated with fewer cerebral white matter lesions, suggesting that it may be useful in preventing dementia. […]

    Tea and coffee are widely consumed beverages that contain caffeine, polyphenols, and vitamins, which possess neuroprotective effects. Several epidemiological studies have shown that tea and coffee consumption are associated with cognitive benefits in older adults…. In some studies did not classified types of tea such as black tea and green tea strictly…. Neuroprotective ingredients containing beverages are known to be epigallocatechin gallate for green tea, theaflavins for black tea, and chlorogenic acid and caffeic acid for coffee, those ingredients have antioxidant and anti-inflammatory effects […]

    Aging is a major risk factor for dementia and causes brain changes, such as brain atrophy, hippocampal atrophy, and an increase in cerebral white matter lesions. Although green tea and coffee are expected to have positive effects on mitigating cognitive decline, the link between tea or coffee consumption and brain changes in older adults remains poorly understood. Nonetheless, increased green tea consumption has been linked to reduced annual hippocampal atrophy at the population level and regular coffee consumption has been linked to higher cortical thickness. […]

    Nature: Green tea consumption and cerebral white matter lesions in community-dwelling older adults without dementia

    Authors: Shutaro Shibata, Moeko Noguchi-Shinohara, Ayano Shima, Taro Ozaki, Yuta Usui, Yasuyuki Taki, Kazuhiro Uchida, Takanori Honda, Jun Hata, Tomoyuki Ohara, Tatsuya Mikami, Tetsuya Maeda, Masaru Mimura, Kenji Nakashima, Jun-ichi Iga, Minoru Takebayashi, Toshiharu Ninomiya & Kenjiro Ono.

  10. Servetus says:

    DEA releases Telehealth Special Registration Proposal:

    On January 15, 2025, the US Drug Enforcement Administration (DEA) released a proposed rule entitled Special Registrations for Telemedicine and Limited State Telemedicine Registrations. This proposed rule would establish three special registrations, creating pathways for telehealth practitioners to prescribe, and online platforms to dispense, certain controlled substances via telemedicine after flexibilities expire on December 31, 2025. However, it is unclear whether the incoming Trump administration will move forward with the proposed approach for special registration.

    Current federal telehealth-focused controlled substance prescribing flexibilities, initially invoked in response to the COVID-19 public health emergency (PHE), will expire December 31, 2025.

    Absent the flexibilities, current law would require telemedicine providers to perform an in-person medical evaluation of a patient prior to prescribing a controlled substance, with certain limited exceptions. One such exception is for providers who hold a “special registration,” the details of which were left within the DEA’s purview. This is the first time the DEA has proposed a special registration since the passage of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008, when it was originally required. […]

    J D Supra: DEA Releases Long-Awaited Telehealth Special Registration Proposal, but Adoption Is Uncertain

  11. Servetus says:

    Smoking opioids is associated with a two-thirds lower mortality rate compared to injecting:

    23-Jan-2025–A new study published today in the scientific journal Addiction has found that opioid smoking appears to be associated with lower mortality risk compared with opioid injecting. The authors, however, caution that opioid smoking still carries a substantial overdose risk and that these results should not be interpreted as suggesting that opioid smoking is safe. […]

    The analysis found a mortality rate of 6.5 per 1000 person-years in the smoking cohort and 9.7 in the injection cohort. The mortality rate ratio was 0.67, meaning people who primarily smoked opioids died at two-thirds of the rate of people who primarily injected opioids.

    Although smoking rather than injecting opioids may mitigate some risks, smoking opioids still carries a significant risk of death. Smoking recently surpassed injection as the most common route of administration identified among opioid-related fatal overdoses in the United States1, likely driven in part by the rising popularity of opioid smoking and the decrease in opioid injecting.

    Lead author Dr. George Karandinos, a clinical and research fellow at Massachusetts General Hospital and Harvard Medical School, comments: “Smoking opioids instead of injecting likely reduces injection-associated complications like the transmission of HIV and hepatitis C and other serious infections. […]

    AAAS Public Science News Release: Smoking opioids is associated with lower mortality than injecting but is still high-risk

    Wiley Online Library: Mortality risk among individuals who smoke opioids compared to those who inject: a propensity scored-matched cohort analysis of United States national treatment data

    Authors: George Karandinos, Jay Unick, Daniel Ciccarone.

    • Pete Guither's blog reader says:

      I strongly disagree with Bill O’Reilly’s stance on marijuana. His views are outdated and not supported by scientific evidence. Marijuana has been shown to have numerous medical benefits and should be legalized.

  12. Servetus says:

    The Trump administration has rescinded a proposed ban of menthol cigarettes:

    24-JAN-25 — The proposed rule, which had been in the works since mid-2022, was listed as “Withdrawn” as of January 21 on an Office of Management and Budget (OMB) webpage. Approval by the OMB is one of the last steps before a final rule is issued. […]

    When the rule was initially announced, HHS Secretary Xavier Becerra said in a statement that the rule “would help prevent children from becoming the next generation of smokers and help adult smokers quit. Additionally, the proposed [rule represents] an important step to advance health equity by significantly reducing tobacco-related health disparities.” An estimated 80% of Black smokers smoke menthol cigarettes, compared with 30% of white smokers. […]

    One possible reason previously suggested by observers for the delay is that the Biden administration might have been afraid that issuing the rule could alienate Black voters before the presidential election. But even after the election, the rule did not move forward. […]

    The action by the Trump administration is not a surprise, according to Erika Sward, assistant vice president for nationwide advocacy at the American Lung Association (ALA). “It is standard at the beginning of a new presidential administration for all rules that are pending to be swept back to the agencies,” she said in a phone interview. The ALA “remains deeply disappointed that President Biden did not finalize these two rules — the menthol cigarette rule and a rule banning flavored cigars — when he had the opportunity. Lives will be lost because of it.” […]

    MedPage Today: Trump Administration Withdraws Plan to Ban Menthol Cigarettes — “Lives will be lost” because the previous administration failed to act, says one advocacy group

Leave a Reply

Your email address will not be published. Required fields are marked *